<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391546</url>
  </required_header>
  <id_info>
    <org_study_id>V211-045</org_study_id>
    <secondary_id>ZTV03C</secondary_id>
    <secondary_id>V211-045</secondary_id>
    <secondary_id>2009-012458-19</secondary_id>
    <nct_id>NCT01391546</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)</brief_title>
  <official_title>An Open-label, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ZOSTAVAX When Administered by Intramuscular Route or Subcutaneous Route to Subjects of 50 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVES

      Two co-primary objectives are:

        -  To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route
           (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC)

        -  To demonstrate that ZOSTAVAX administered by IM route induces an acceptable fold-rise of
           varicella zoster virus (VZV) antibody titre from pre to 4-week post-vaccination

      SECONDARY OBJECTIVES

      Immunogenicity objectives

        -  To evaluate the immunogenicity as measured by VZV antibody titre at 4 weeks following
           ZOSTAVAX administered by IM or SC route

        -  To evaluate the immune response as measured by a second assay, the VZV Interferon gamma
           Enzyme-linked immunospot (ELISPOT) at 4 weeks following ZOSTAVAX administered by IM or
           SC route

      Safety objective

      - To describe the safety profile of ZOSTAVAX administered by IM or SC route
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2011</start_date>
  <completion_date type="Actual">October 15, 2012</completion_date>
  <primary_completion_date type="Actual">October 15, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination</measure>
    <time_frame>4 week post-vaccination</time_frame>
    <description>Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route</measure>
    <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
    <description>Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route</measure>
    <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
    <description>Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies</measure>
    <time_frame>4 week post-vaccination</time_frame>
    <description>Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10^6 Peripheral Blood Mononuclear Cells (PBMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies</measure>
    <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
    <description>Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction</measure>
    <time_frame>up to 28 days after vaccination</time_frame>
    <description>Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Report at Least 1 Systemic Adverse Event</measure>
    <time_frame>up to Day 28 after vaccination</time_frame>
    <description>An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Report at Least 1 Serious Adverse Event</measure>
    <time_frame>up to 35 days after vaccination</time_frame>
    <description>A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>ZOSTAVAX intramuscular (IM) route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 0.65 mL via IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZOSTAVAX subcutaneous (SC) route</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 0.65 mL via SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZOSTAVAX</intervention_name>
    <description>1 dose 0.65 mL</description>
    <arm_group_label>ZOSTAVAX intramuscular (IM) route</arm_group_label>
    <arm_group_label>ZOSTAVAX subcutaneous (SC) route</arm_group_label>
    <other_name>V211</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged &gt;=50 years

          -  Varicella history-positive or residence for &gt;30 years in a country with endemic VZV
             infection

        Exclusion Criteria:

          -  Febrile illness

          -  History of hypersensitivity or anaphylactoid reaction to any of the vaccine components

          -  Prior herpes zoster episode clinically diagnosed or exposure to varicella or herpes
             zoster within the 4 weeks prior to vaccination

          -  Prior receipt of varicella or zoster vaccine

          -  Active untreated tuberculosis

          -  Thrombocytopenia, any other coagulation disorder contraindicating intramuscular
             injection

          -  Receipt of medication / vaccine that may interfere with study assessments

          -  Known or suspected immune dysfunction

          -  User of recreational / illicit drugs or subject with alcohol abuse or dependence
             within the last year

          -  Any condition that might interfere with the interpretation of the study,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Spain</country>
  </removed_countries>
  <results_reference>
    <citation>Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. Vaccine. 2015 Feb 4;33(6):789-95. doi: 10.1016/j.vaccine.2014.12.024. Epub 2014 Dec 30.</citation>
    <PMID>25555381</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <results_first_submitted>October 20, 2017</results_first_submitted>
  <results_first_submitted_qc>October 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2017</results_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ZOSTAVAX Intramuscular (IM) Route</title>
          <description>Single dose of 0.65 mL via IM injection</description>
        </group>
        <group group_id="P2">
          <title>ZOSTAVAX Subcutaneous (SC) Route</title>
          <description>Single dose of 0.65 mL via SC injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>History of Herpes Zoster (HZ)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZOSTAVAX Intramuscular (IM) Route</title>
          <description>Single dose of 0.65 mL via IM injection</description>
        </group>
        <group group_id="B2">
          <title>ZOSTAVAX Subcutaneous (SC) Route</title>
          <description>Single dose of 0.65 mL via SC injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="177"/>
            <count group_id="B3" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50-59 years of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="177"/>
                    <count group_id="B2" value="177"/>
                    <count group_id="B3" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="177"/>
                    <count group_id="B2" value="177"/>
                    <count group_id="B3" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70 years of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="177"/>
                    <count group_id="B2" value="177"/>
                    <count group_id="B3" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="177"/>
                    <count group_id="B2" value="177"/>
                    <count group_id="B3" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Vaccination</title>
          <description>Age of all vaccinated participants at Day 0 (time of vaccination)</description>
          <population>One enrolled participant in IM arm withdrew prior to vaccination</population>
          <units>Years of Age</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="176"/>
                    <count group_id="B2" value="177"/>
                    <count group_id="B3" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="8.3"/>
                    <measurement group_id="B2" value="62.6" spread="8.5"/>
                    <measurement group_id="B3" value="62.6" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination</title>
        <description>Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).</description>
        <time_frame>4 week post-vaccination</time_frame>
        <population>All randomised participants who had received the study vaccine, had at least one valid immunogenicity evaluation for VZV antibody and had post-vaccination data available for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination</title>
          <description>Blood samples taken at 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).</description>
          <population>All randomised participants who had received the study vaccine, had at least one valid immunogenicity evaluation for VZV antibody and had post-vaccination data available for endpoint.</population>
          <units>gpELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.3" lower_limit="350.6" upper_limit="445.6"/>
                    <measurement group_id="O2" value="391.7" lower_limit="348.9" upper_limit="439.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was achieved if the lower bound of the 2-sided 95% confidence interval (CI) for the GMT ratio was greater than 2/3</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>longitudinal regression model</method>
            <method_desc>Model adjusted for pre-vaccination titres and age at vaccination in years</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT IM route divided by GMT SC route</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route</title>
        <description>Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination</description>
        <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
        <population>All randomised participants who had received the study vaccine via IM route, had at least one valid immunogenicity evaluation for VZV antibody and had post-vaccination data available for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: IM Route</title>
          <description>Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-dose/GMT Pre-vaccination</description>
          <population>All randomised participants who had received the study vaccine via IM route, had at least one valid immunogenicity evaluation for VZV antibody and had post-vaccination data available for endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.4" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Acceptability was demonstrated if the lower bound of the two-sided 95% CI was &gt;1.4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMFR</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>GMFR = GMT Post-vaccination/GMT Pre-vaccination</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route</title>
        <description>Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination</description>
        <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
        <population>All randomised participants who had received the study vaccine via SC route, had at least one valid immunogenicity evaluation for VZV antibody and had post-vaccination data available for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) in VZV Antibody Titre: SC Route</title>
          <description>Blood sample taken at predose (Day 0) and 4 weeks post vaccination to determine the geometric mean titre (GMT) of VZV antibodies via gpELISA. The GMFR was calculated as GMT Post-vaccination/GMT Pre-vaccination</description>
          <population>All randomised participants who had received the study vaccine via SC route, had at least one valid immunogenicity evaluation for VZV antibody and had post-vaccination data available for endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.2" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies</title>
        <description>Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10^6 Peripheral Blood Mononuclear Cells (PBMC)</description>
        <time_frame>4 week post-vaccination</time_frame>
        <population>All randomised participants in the ELISPOT subset (predetermined protocol-defined sites) who had received the study vaccine and had valid post-vaccination data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Count (GMCs) of VZV Interferon Gamma ((IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) Antibodies</title>
          <description>Blood samples taken 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMC's. Results were reported as ELISPOT count/10^6 Peripheral Blood Mononuclear Cells (PBMC)</description>
          <population>All randomised participants in the ELISPOT subset (predetermined protocol-defined sites) who had received the study vaccine and had valid post-vaccination data for endpoint.</population>
          <units>ELISPOT count/10^6 PBMC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.8" lower_limit="175.2" upper_limit="251.3"/>
                    <measurement group_id="O2" value="195.7" lower_limit="161.9" upper_limit="236.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies</title>
        <description>Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.</description>
        <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
        <population>All randomised participants in the ELISPOT subset (predetermined protocol-defined sites) who had received the study vaccine and had valid pre- and post-vaccination data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of IFN-γ ELISPOT Antibodies</title>
          <description>Blood samples taken pre-vaccination and 4 weeks post-vaccination to determine the IFN-γ ELISPOT GMFR.</description>
          <population>All randomised participants in the ELISPOT subset (predetermined protocol-defined sites) who had received the study vaccine and had valid pre- and post-vaccination data for endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.8" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.7" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction</title>
        <description>Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.</description>
        <time_frame>up to 28 days after vaccination</time_frame>
        <population>All vaccinated participants who had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Report at Least 1 Injection-site Adverse Reaction</title>
          <description>Participants entered data into daily diary card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain for 1st 4 days post-vaccination. Additionally, injection site reactions not prompted on diary card (unsolicited) were collected up 28 days post-vaccination. All injection site reactions (solicited or unsolicited) were recorded.</description>
          <population>All vaccinated participants who had follow-up safety data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="27.1" upper_limit="41.6"/>
                    <measurement group_id="O2" value="64.4" lower_limit="56.9" upper_limit="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Report at Least 1 Systemic Adverse Event</title>
        <description>An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.</description>
        <time_frame>up to Day 28 after vaccination</time_frame>
        <population>All vaccinated participants who had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Report at Least 1 Systemic Adverse Event</title>
          <description>An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized. These events included rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events.</description>
          <population>All vaccinated participants who had follow-up safety data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="17.3" upper_limit="30.2"/>
                    <measurement group_id="O2" value="22.6" lower_limit="16.7" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Report at Least 1 Serious Adverse Event</title>
        <description>A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.</description>
        <time_frame>up to 35 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZOSTAVAX Intramuscular (IM) Route</title>
            <description>Single dose of 0.65 mL via IM injection</description>
          </group>
          <group group_id="O2">
            <title>ZOSTAVAX Subcutaneous (SC) Route</title>
            <description>Single dose of 0.65 mL via SC injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Report at Least 1 Serious Adverse Event</title>
          <description>A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an &quot;other important medical event&quot; based on medical judgement. The percentage of participants who reported an SAE within 35 days of vaccination were recorded.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" upper_limit="3.1"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 35 days</time_frame>
      <desc>Safety population included all participants who received vaccine and had safety follow-up data available.</desc>
      <group_list>
        <group group_id="E1">
          <title>ZOSTAVAX Intramuscular (IM) Route</title>
          <description>Single dose of 0.65 mL via IM injection</description>
        </group>
        <group group_id="E2">
          <title>ZOSTAVAX Subcutaneous (SC) Route</title>
          <description>Single dose of 0.65 mL via SC injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="176"/>
                <counts group_id="E2" events="94" subjects_affected="94" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="176"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="176"/>
                <counts group_id="E2" events="67" subjects_affected="67" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators must first obtain written consent from Sponsor. If consent is given, all abstracts manuscripts, texts, or presentation, etc. will be sent to Sponsor for review and approval prior to their publication or presentation. Sponsor shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

